Acetylsalicylic acid as an anti-platelet agent: what forms should be used, according to evidence-based medicine?
Abstract
This analytic paper reviews the evidence on effectiveness, benefits and limitations of one of the best-studied antiplatelet agents – acetylsalicylic acid (ASA). The results of clinical trials, together with so called “gastro-toxicity” of ASA, or Aspirin, and a need for long-term anti-platelet therapy, were the basis for development of various Aspirin forms – soluble, with controlled release, enteric-coated, local (cutaneous), buffer, and combined (Aspirin plus antacids). Currently, the minimal gastro-toxicity has been demonstrated for enteric-coated forms. Specifics of bio-availability, laboratory effects, gastro-intestinal tolerability, and safety could not be the main criteria for choosing a medication form. The choice of an ASA form is defined by the evidence on risk reduction by this form. The extensive evidence on Aspirin as an anti-platelet agent has been obtained in clinical trials using standard ASA. For enteric-coated ASA forms, the evidence on end-point reduction, including mortality reduction, is also available. For other “improved” Aspirin forms, such as buffer, soluble and combined, this evidence is lacking; therefore, their choice could be based only on similarity of laboratory effects and expected lower gastro-toxicity.
References
1. Antiplatelet Trialist' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: I. Prevention of death myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
2. Antiplatelet Trialist' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
3. Patrono С., Bachmann F., Baigent C. et al. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Expert consensus document on the use of antiplatelet agents. Eur Heart J 2004; 25: 166-81.
4. The Clopidogrel in Unstable Angina to Prevent Recurrent Events trial investigators. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
5. Clarke R.J., Mayo G., Price P., Fitzgerald G.A. Suppresion of thromboxane A2 but not systemic prostacyclin by controlled-released aspirin. N Eng J Med 1991; 325: 1137-41.
6. Keimowitz R.M., Pulvermacher G., Mayo G., Fitzgerald D.J. Aspirin and platelets: transdermal modification of platelet function: a dermal aspirin preparation selectively inhibits platelet function; a dermal aspirin preparation selectively inhibits platelet cyclooxygenase and preserve prostacyclin biosynthesis. Circulation 1993; 88: 556-61.
7. Jaszewsky R. Frequency of gastroduodenal lesions in asymptomatic patients on chronic aspirin or nonsteroidal anti-inflammatory drug therapy. J Clin Gastroenterol 1990; 12: 10-3.
8. Walker J., Robinson J., Stewart J. et al. Does enteric-coated aspirin result in a lower incidence of gastrointestinal complications compared to normal aspirin? Interact Cardiovasc Thorac Surg 2007; 6(4): 519-22.
9. Cole A.T., Hudson N., Liew L.C. et al. Protection of human gastric mucosa against aspirin-enteric coating or dose reduction? Aliment Pharmacol Ther 1999; 13(2): 187-93.
10. Savon J., Allen M.L., DiMarino A.J.Jr., et al. Gastrointestinal blood loss with low-dose (325 mg) plain and enteric-coated aspirin administration. Am J Gastrointerol 1995; 90: 581.
11. Kelly J.P., Kaufman D.W., Jugelon J.M. et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348: 1413.
12. Hawthorne A.B., Mahida Y.R., Cole A.T., Hawkey C.J. Aspirin-induced gastric mucosal damage; prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol 1991; 32: 77-83.
13. Dietz R., Rauch B. Leitlinie zur Diagnose und Behandlung der chronischen koronaren Herzerkrankung der Deutschen Gesellschaft fr Kardiologie -Herz-und Kreislaufforschung (DGK). Z Kardiol 2003; 92: 501-21.
14. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.
15. Baigent C., Collins R., Appleby P. et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomized comparision of intravenous streptokinase, oral aspirin, both, or neither. BMJ 1998; 316: 1337-43.
16. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357: 89-95.
Review
For citations:
Averkov O.V. Acetylsalicylic acid as an anti-platelet agent: what forms should be used, according to evidence-based medicine? Cardiovascular Therapy and Prevention. 2010;9(2):61-68. (In Russ.)
Views:
1601
Email this article 
